Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Diabetes Therapy

Volumn 9, Issue 1, 2018, Pages 193-207

  Hollander, Priscilla ^a   Liu, Jie ^b   Hill, Julie ^b   Johnson, Jeremy ^b   Jiang, Zhi Wei ^c   Golm, Gregory ^b   Huyck, Susan ^b   Terra, Steven G ^d   Mancuso, James P ^d   Engel, Samuel S ^b   Lauring, Brett ^b  

^a Baylor Endocrine Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD China   (China)

^d PFIZER INC   (United States)

Author keywords

Ertugliflozin; Glycemic control; Sodium glucose cotransporter 2 inhibitor; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

ERTUGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION;

EID: 85041506485     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-017-0354-4     Document Type: Article

References (18)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40:S1–135.
2. Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes Obes Metab. 2008;10(Suppl 1):1–7.
3. Andersen SE, Christensen M. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br J Clin Pharmacol. 2016;82:1291–302.
4. González-Ortiz M, Guerrero-Romero J, Violante-Ortiz R, et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complicat. 2009;23:376–9.
5. Paneni F, Luscher TF. Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Cardiol. 2017;120:S17–27.
6. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721–8.
7. Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13103.
8. Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13116.
9. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80.
10. Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2017. https://doi.org/10.1007/s13300-017-0337-5.
11. University of Oxford. HOMA calculator, 2004. http://www.dtu.ox.ac.uk/homacalculator/. Accessed Oct 16, 2017.
12. Liang K-Y, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ser B. 2000;62:134–48.
13. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26.
14. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996;19:849–56.
15. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50.
16. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700.
17. Nauck M, del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. Dtsch Med Wochenschr. 2013;138(Suppl 1):S6–15.
18. Kalra S, Singh V, Nagrale D. Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review. Adv Therapy. 2016;33:1502–18.